A result of research by Pierre Fabre
NAVELBINE® (vinorelbine), originally discovered by the CNRS research team of Professor Pierre Potier, was developed into a finished drug by Pierre Fabre Laboratories. It was granted its first registration in France, ...
Digestive problems are more frequent with oral chemotherapy than with intravenous chemotherapy
Research in oncology is Pierre Fabre’s area of excellence. It represents the major therapeutic field of the Group and has been supported for several years by a very significant effort. Around 50% of R&D investments in the Group’s medical product branch are currently...
The development of an oral form of NAVELBINE® represented a huge step towards improving the comfort and quality of life of patients by avoiding hospitalisation and the stress associated with infusion and also reducing the global costs of treatment. NAVELBINE® Oral is now registered in a large number of countries.